SCHEMBL4674286

SCHEMBL4674286

O=C(C=C(O)c1nc[nH]n1)c1ccoc1Oc1ccccc1C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
CYP1A1 P04798 1/20 0.32
ABCB1 P08183 1/20 0.32
CYP1B1 Q16678 1/20 0.32
NOTUM Q6P988 1/20 0.31
MRGPRX4 Q96LA9 1/20 0.31
MAOB P27338 1/20 0.31
NFE2L2 Q16236 1/20 0.31
KMO O15229 1/20 0.31
PPARG P37231 1/20 0.31
FAAH O00519 1/20 0.31
BCHE P06276 1/20 0.31
ACHE P22303 1/20 0.31
P2RY1 P47900 1/20 0.31
RORC P51449 1/20 0.31
MCL1 Q07820 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4670704 0.85 RXRA (0.33) RXRARXRBRXRGNOTUMMRGPRX4
SCHEMBL4675173 0.85 RAB9A (0.33) CYP1A1ABCB1CYP1B1
SCHEMBL4674906 0.85 CYP1A1 (0.40) CYP1A1ABCB1CYP1B1
SCHEMBL4676663 0.83 CYP1A1 (0.36) CYP1A1ABCB1CYP1B1NFE2L2
SCHEMBL4675422 0.83 RXRA (0.33) RXRARXRBRXRGNOTUMMRGPRX4
SCHEMBL4670849 0.82 KDM4C (0.35) PPARG
SCHEMBL4672937 0.81 KDM4E (0.38) MRGPRX4P2RY1
SCHEMBL4674892 0.80 KDM4E (0.32) CYP1A1ABCB1CYP1B1NOTUMKMO
SCHEMBL4674056 0.80 GPR52 (0.35) MAOBKMO
SCHEMBL4679125 0.80 MRGPRX4 (0.37) RXRARXRBRXRGNOTUMMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 RXRA 1268/4885RXRB 1235/4885RXRG 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.